Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemoimmunotherapy for canine lymphosarcoma.

G H Theilen, M Worley, E Benjamini

    Journal of the American Veterinary Medical Association
    |March 15, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The hHFE gene of browsing and grazing rhinoceroses: a possible site of adaptation to a low-iron diet.

    Blood cells, molecules & diseases·2001
    Same author

    Primary Mycobacterium avium complex infections correlate with lowered cellular immune reactivity in Matschie's tree kangaroos (Dendrolagus matschiei).

    The Journal of infectious diseases·1998
    Same author

    Hypervariable epitope constructs as a means of accounting for epitope variability.

    Vaccine·1994
    Same author

    Multi-registry databases used as an outcome management tool.

    Journal of AHIMA·1994
    Same author

    Human microvascular endothelial cell toxicity caused by Brazilian purpuric fever-associated strains of Haemophilus influenzae biogroup aegyptius.

    The Journal of infectious diseases·1994
    Same author

    An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation.

    AIDS research and human retroviruses·1993

    Chemotherapy and immunotherapy significantly improved survival times in dogs with lymphosarcoma. Dogs receiving both treatments showed a mean survival of 341 days, outperforming those treated with drugs alone.

    Area of Science:

    • Veterinary Oncology
    • Immunotherapy
    • Chemotherapy

    Background:

    • Lymphosarcoma is a common cancer in dogs.
    • Effective treatment strategies are crucial for improving prognosis.

    Purpose of the Study:

    • To evaluate the efficacy of multi-drug chemotherapy combined with autogenous vaccine immunotherapy in dogs with lymphosarcoma.
    • To assess the impact of clinical staging on treatment outcomes and survival.

    Main Methods:

    • A total of 157 dogs with lymphosarcoma were studied; 67 received treatment.
    • Treated dogs received four-drug combinations, with 20 also receiving autogenous vaccine.
    • Clinical staging was used to correlate prognosis with treatment response.

    Main Results:

    Related Experiment Videos

    • 90% of dogs treated with multi-drug chemotherapy showed clinical improvement.
    • 80% of improved dogs achieved complete or partial remission; 67% achieved complete remission.
    • Mean survival time for chemotherapy alone was 138 days vs. 30 days for untreated dogs.
    • Chemotherapy and immunotherapy resulted in a mean survival time of 341 days.
    • Dogs in complete remission at vaccination survived significantly longer (P < 0.01).

    Conclusions:

    • Multi-drug chemotherapy is effective in managing canine lymphosarcoma.
    • Combination therapy with chemotherapy and immunotherapy significantly prolongs survival.
    • Clinical staging aids in predicting prognosis and optimizing treatment strategies.